Sign inJoin waitlistJoin the waitlist

YS

Yi Shi

Pharmacist · University of California Davis Health

Credentials: ·

History

University of California Davis Health
Present

Research

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
The Lancet Oncology · 2021 · 369 citations
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma
European Urology · 2024 · 134 citations
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a…
The Lancet Oncology · 2019 · 80 citations

Michael Eadon
3 papers · 3 as a fellow
Jeffrey Caterino
2 papers
Joaquim Bellmunt
2 papers
Katherine Buck
2 papers
Maha Hussain
2 papers
ND
Nicole Davarpanah
2 papers
Petros Grivas
2 papers
Sia Daneshmand
2 papers
Aditya Bardia
1 paper
Alexandra Drakaki
1 paper
AA
Alexey Aleshin
1 paper
Cathy Eng
1 paper